

MINI REVIEW

MARINE PHARMACOLOGY IN 2000: ANTITUMOR AND CYTOTOXIC COMPOUNDS

Alejandro M.S. MAYER^{1*} and Kirk R. GUSTAFSON²

¹Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA

²Molecular Targets Development Program, Center for Cancer Research, Frederick, MD, USA

During 2000, marine antitumor pharmacology research aimed at the discovery of novel antitumor agents was published in 85 peer-reviewed articles. The purpose of this article is to present a structured review of the antitumor and cytotoxic properties of 143 marine natural products, many of them novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids and peptides. The organisms yielding these bioactive compounds comprised a taxonomically diverse group of marine invertebrate animals, algae, fungi and bacteria. Antitumor pharmacological studies were conducted with 19 marine natural products in a number of experimental and clinical models that defined or further characterized their mechanisms of action. Potentially promising *in vitro* cytotoxicity data generated with murine and human tumor cell lines were reported for 124 novel marine chemicals with as yet undetermined mechanisms of action. Noteworthy is the fact that marine anticancer research clearly remains a multinational effort, involving researchers from Austria, Australia, Brazil, Canada, England, France, Germany, Greece, Indonesia, Italy, Japan, New Zealand, Russia, Spain, South Korea, Switzerland, Taiwan, the Netherlands and the United States. Finally, this 2000 overview of the marine pharmacology literature highlights the fact that the discovery of novel marine antitumor agents continued at the same high level of research activity as during 1998 and 1999.

© 2003 Wiley-Liss, Inc.

Key words: marine; antitumor; cytotoxic; cancer; pharmacology; review

The purpose of this article is to review the research literature published during 2000 in the field of marine antitumor pharmacology using a format similar to the one used in our previous 2 reports, which reviewed the marine antitumor pharmacology research during 1998 and 1999.^{1,2} Consistent with our previous 2 articles, only those reporting on the antitumor pharmacology or cytotoxicity data of marine compounds with established chemical structures (Figs. 1 and 2) are included in the present review and are presented in alphabetical order in Tables I and II. Research articles reporting on novel preclinical and/or clinical antitumor pharmacological research of marine chemicals with determined mechanisms of action have been presented in Table I and are discussed with a focus on the new information on the mechanism of action. On the other hand, reports on the cytotoxicity of marine chemicals with undetermined mechanisms of action are grouped in Table II. Publications on the preclinical antitumor or cytotoxic activity of synthetic analogues of marine metabolites as well as that of marine extracts or as yet structurally uncharacterized marine compounds have been excluded from the present review, although several promising studies were reported during 2000.^{3–5}

2000 ANTITUMOR PHARMACOLOGY OF MARINE NATURAL PRODUCTS WITH DETERMINED MECHANISMS OF ACTION

Table I provides a summary of the main conclusions of 23 studies that reported research involving 19 different marine compounds (selected structures are illustrated in Fig. 1). Reports on clinical trials are not included in Table I but are discussed in the text of the article.

New information became available during 2000 on the pharmacology of Bryostatin-1, Cryptophycins, Didemnin B, Discodermolide, Dolastin 10, Ecteinascidin-743 and Eleutherobin, marine compounds also included in both our 1998 and 1999 reviews.^{1,2}

Five studies were published during 2000 on the preclinical and clinical pharmacology of Bryostatin-1. Cartee *et al.*⁶ investigated whether chronic exposure to the macrolide Bryostatin-1 could circumvent the resistance to ionizing radiation-induced apoptosis conferred by the overexpression of the antiapoptotic gene Bcl-2 in human histiocytic lymphoma U937 cells. Their findings suggest that Bryostatin-1 sensitizes Bcl-2 overexpressing human leukemia cells to ionizing radiation-mediated antiproliferative effects through a mechanism that does not appear to involve the induction of apoptosis. With the purpose of contributing to clinical trials with the combination of Bryostatin-1 and paclitaxel, Koutcher *et al.*⁷ determined the effect of the sequential use of both agents on tumor growth, mitotic entry and blood flow using a tumor-bearing mouse model. Their studies determined that there is a definite sequence dependence of this combination, as prior treatment with Bryostatin-1 inhibited tumor responses to paclitaxel. Furthermore, the authors concluded that when phase 1 clinical trials are started, the “sequence of paclitaxel followed by bryostatin will be critical in the clinical trial design.”⁷ Mohammad *et al.*⁸ studied the antitumor effects of the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen alone or in combination with Bryostatin-1 on a xenograft model for resistant diffuse large cell lymphoma (DLCL) in mice with severe combined immune deficiency. The *in vitro* and *in vivo* results reported documented that combining Bryostatin-1 with the CHOP regimen enhanced the effect against DLCL, thus suggesting further clinical investigation of this novel marine agent for the treatment of lymphomas. Two clinical reports were published during 2000. Pagliaro *et al.*⁹ reported the results of a single-institution phase 2 trial of Bryostatin-1 in patients with metastatic renal cell carcinoma, a type of cancer for which there is currently a poor prognosis and no optimal systemic therapy available. Although 2 out of a total of 30 patients evi-

Grant sponsor: the National Institute of Environmental Health Sciences, National Institutes of Health; Grant number: R03 ES10138-01.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the National Institute of Environmental Health Sciences, National Institutes of Health.

*Correspondence to: Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, 555 31st Street, Downers Grove, IL 60515. Fax: +630-971-6414. E-mail: amayer@midwestern.edu

Received 12 August 2002; Revised 4 December 2002; Accepted 20 January 2003

DOI 10.1002/ijc.11080




FIGURE 1 – Structures of marine natural products reported in 2000 with established mechanisms of action.

denced significant tumor regression, the median survival for the patients was 13.1 months, which differed little from overall median survival for patients with metastatic renal cell carcinoma, currently 1 year. Thus, the study demonstrated that “there is minimal, if any, clinically relevant single-agent activity of Bryostatin-1” at the dose and schedule used.⁹ Varterasian *et al.*¹⁰ reported on a phase 2 trial of Bryostatin-1 in 25 patients with relapsed low-grade non-Hodgkin’s lymphoma (LG-NHL) or chronic lymphocytic leukemia (CLL). Bryostatin-1 alone resulted in 1 complete remission of a patient with LG-NHL and 2 partial remissions of patients with CLL. The authors concluded that Bryostatin-1 “resulted in a modest although definite activity as a single agent.”¹⁰

During 2000, 3 preclinical studies were reported with the marine depsipeptides Cryptophycins, a family of novel antimitotic compounds. Panda *et al.*¹¹ reported their research with the antitumor compound Cryptophycin-52, a novel member of the cryptophycin family, currently produced by total chemical synthesis, which suppresses microtubule dynamics. Cryptophycin-52 at low picomolar concentrations was shown to inhibit cancer cell proliferation by stabilizing spindle microtubules, binding tightly and noncovalently to a single high-affinity site on tubulin, while also inducing a conformational change in the tubulin molecule. Lilly Research Laboratories reported 2 preclinical animal studies with Cryptophycins.^{12,13} The investigators undertook extensive research with Cryptophycin-52 and -55, noting these agents can be added to other anticancer agents simultaneously or sequentially, thus leading to additive to greater-than-additive tumor responses in several human tumor xenograft models (*e.g.*, colon and ovarian carcinoma) and “warrant further investigation.”¹¹

Three studies were reported during 2000 on the preclinical and clinical pharmacology of the Didemnin depsipeptides.¹⁴ This contrasts with the 5 pharmacological studies with Didemnin B and Aplidine published during 1999.¹ In a preclinical study, Ahuja *et al.*¹⁴ determined that the Didemnins were moderately potent inhibitors of protein synthesis *in vitro* and that the intact depsipeptide ring was required for this activity. Interestingly, a correlation

was noted between inhibition of protein synthesis in cell lysates and in human adenocarcinoma MCF-7 cells, suggesting that protein synthesis may be inhibited by the binding of Didemnins to ribosome-EF-1 α complexes in both cell types. Kucuk *et al.*¹⁵ reported on a phase 2 trial of Didemnin B in previously treated non-Hodgkin’s lymphoma patients who had failed initial therapy and had a poor prognosis. Unfortunately, Didemnin B appeared to have only modest activity in the 29 patients who received the marine antitumor agent, while also concomitantly showing evidence of considerable toxicity to this patient population. In an extensive pharmaceutical formulation study with dehydrodidemnin B or Aplidine, Nuijen *et al.*¹⁶ completed a series of studies that resulted in the development of a freeze-dried formulation that appeared to be a stable parenteral pharmaceutical dosage that will contribute significantly to phase 1 clinical testing of Aplidine.

During 2000, one article was published discussing research with the marine polyketide Discodermolide. Martello *et al.*¹⁷ reported on a schedule-independent synergistic combination of Taxol and Discodermolide, in 4 different human carcinoma cell lines, which was surprising in view of the fact that the mechanism of action of both drugs has been proposed to be similar. The authors suggest that one possibility to explain this synergy is that Discodermolide has additional targets that could cause an increase in apoptosis, a mechanism unrelated to the tubulin-binding properties of Discodermolide. The authors conclude by suggesting that Taxol and Discodermolide may constitute a promising chemotherapeutic combination “that merits exploration.”¹⁷

A phase 1 clinical study with the pentapeptide Dolastin 10 isolated from the marine mollusk *Dolabella auricularia* was reported during 2000. Madden *et al.*¹⁸ determined the maximum tolerated dose, clinical pharmacokinetics and metabolism of Dolastin 10 as well as hematological and nonhematological toxicity and antitumor activity in 22 patients with pathologically advanced solid tumors using a single rapid i.v. infusion repeated every 22 days. Although no anticancer response was observed in the patients, the investigators concluded their extensive study by suggesting that “further study of escalated Dolastin 10 dosing with




FIGURE 2 – Selected structures of new marine compounds with cytotoxic or antitumor activity reported in 2000.

cytokine support is warranted” to minimize the myelosuppressive effects of this marine natural product.¹⁸

Research with the isoquinoline alkaloid Ecteinascidin-743, an antitumor agent originating from the Caribbean tunicate *Ecteinascidia turbinata* continued to be very active during 2000. In addition to 3 reports published in 1998² and 4 articles in 1999,¹ 3 preclinical and 1 clinical article were published during 2000. Jin *et al.*¹⁹ reported that physiologically relevant nM concentrations of Ecteinascidin-743 blocked the activation of the human P glycoprotein gene (MDR1) promoter by multiple stress inducers (*e.g.*, UV irradiation) in MDR1-transfected human colon carcinoma cells. The investigators thus suggested that Ecteinascidin-743 might become the “prototype for a distinct class of transcription-targeted chemotherapeutic agents” and perhaps become adjuvants for the treatment of multidrug resistant tumors.¹⁹ In an accompanying article, Minuzzo *et al.*²⁰ investigated the interference of transcriptional activation by Ecteinascidin-743 in transfected mouse NIH 3T3 fibroblasts, and they observed that Ecteinascidin behaved as a promoter-specific, transcription-interfering inhibitor. The effect was very rapid, a 1-min preincubation being sufficient, and it was observed at pharmacological concentrations (nM) that correlated with those observed in the plasma of patients undergoing clinical trials. Garcia-Nieto *et al.*^{21,22} in 2 separate publications, using unrestrained molecular dynamics simulations, studied complexes of Ecteinascidin-743 with 2 DNA target sequences in aqueous solutions. They demonstrated that drug binding causes the widening of the minor groove, a bending toward the major groove, and perhaps increased DNA binding specificity through putative protein-DNA interactions, thus providing further insight into the mechanism of anticancer activity of this compound. Van Kestern *et al.*²³ studied the pharmacokinetics and pharmacodynamics of Ecteinascidin-743 in a phase I dose-finding study designed to identify the maximum tolerated dose and dose-limiting toxicities

(DLT). Although considerable interpatient variability was observed at all dose levels evaluated, this phase I trial indicated that Ecteinascidin-743 administered as a 24-hr intravenous infusion every 3 weeks is well tolerated at a dose of 1,500 $\mu\text{g}/\text{m}^2$ with thrombocytopenia and neutropenia as the DLTs.

Antitumor research with the diterpene Eleutherobin, originally isolated from the soft coral *Eleutherobia sp.* from western Australia, also continued during 2000. The single article reviewed in 1998² was followed by 2 articles in 1999¹ and 2 more in 2000 describing the isolation of the marine natural product from the Caribbean octocoral *Erythropodium caribaeorum*. Cinel *et al.*²⁴ studied Eleutherobin and 6 new antimittotic diterpenes and encountered sufficient structural variations in the tubulin-binding regions in these marine natural products to test a recently proposed pharmacophore model for microtubule stabilizing compounds. One of these compounds, Caribaeoside, showed evidence of a significant decrease in the antimittotic activity ($\text{IC}_{50} = 20 \mu\text{M}$) relative to Eleutherobin ($\text{IC}_{50} = 100 \text{ nM}$), thus demonstrating the importance of the B region of the Eleutherobin pharmacophore for tubulin binding and providing initial support for Ojima’s pharmacophore model presented in our previous review.¹ Roberge *et al.*²⁵ in an accompanying article used a novel cell-based assay for antimittotic compounds to characterize 6 new Eleutherobin analogues, whose antimittotic activity ranged from 20 nM to 20 μM . The authors propose that this cell-based antimittotic assay will greatly facilitate the discovery, development and pharmacological characterization of novel antimittotic agents because it selects for both “activity against a particular target” as well as other desirable properties and potentially novel mechanisms of action that may lead to mitotic arrest.²⁵

Table I lists 9 additional marine natural products, with determined mechanisms of action, for which no reports were published during 1998 and 1999:^{1,2} Aragusterol, Ascidiemnin, Fascaplysin,




FIGURE 2 – CONTINUED

an Indanone from *Lyngbya majuscula*, Lyngbyabellin A, Jaspamide, Meloplins A and B and Spisulosine.

In an extensive and detailed study, Fukuoka *et al.*²⁶ carefully characterized the growth-inhibitory activity of Aragusterol A, a steroid isolated from the Okinawan marine sponge *Xestospongia sp.*, against a panel of 14 human cancer cell lines *in vitro*, observing a broad-spectrum growth-inhibitory activity. Interestingly, when Aragusterol A was administered *in vivo* to mice bearing intraperitoneally implanted murine tumors, a similar broad spectrum and high degree of antitumor activity was observed. The investigators concluded that Aragusterol A targeted the G₁ phase of the cell cycle by downregulating cyclin-dependent kinases and G₁ cyclins involved in G₁/S transition, thus blocking the entry of human tumor cells into the S-phase.

Dassonneville *et al.*²⁷ extended current knowledge on the mechanism of action of Ascididemin, a DNA-intercalating alkaloid isolated from the Mediterranean ascidian *Cystodytes dellechiaiei* by focusing their extremely detailed molecular investigation on the effect of this marine natural product on the catalytic activities of topoisomerases I and II, enzymes known to regulate DNA topology. Although the investigators demonstrated that Ascididemin was a poison for purified topoisomerases, studies with several cell lines led them to conclude that neither topoisomerase I nor II could be considered potential cellular targets for this marine natural product. Interestingly, Ascididemin was shown to be a potent inducer of apoptosis in both human and murine leukemia cells. Matsumoto *et al.*²⁸ in a short communication provided interesting evidence that Ascidi-

didemin can cause oxidative damage to DNA via a thiol-dependent conversion of oxygen to DNA-cleaving oxygen radicals, a process that may lead to concomitant DNA fragmentation. Brief but novel information on the structural features in the Ascididemin molecule required for DNA-cleaving activity as well as indications of probable intracellular damage, as evidenced by flow cytometry, were also provided by the authors.

Soni *et al.*²⁹ discovered a potential new use for the marine natural product Fascaplysin, an alkaloid derived from the sponge *Fascaplysinopsis sp.* While screening for inhibitors of cyclin-dependent protein kinases, key enzymes involved in the mammalian cell cycle, they observed that Fascaplysin selectively inhibited Cdk4 kinase *in vitro* with an IC₅₀ = 0.35 μM. Molecular modeling studies showed that Fascaplysin binds to the ATP binding pocket of Cdk4 by “interacting through a bidentate hydrogen bond/acceptor pair.”²⁹ The fact that Fascaplysin caused G₁ arrest not only in normal human fibroblasts but also in both human colon carcinoma and osteogenic sarcoma cell lines makes this marine chemical an interesting candidate for further study of cellular processes regulated by Cdk4 kinase in mammalian cells. Using new gene transcription-based high-throughput assays for inhibitors of activation of the vascular endothelial growth factor gene (VEGF), an angiogenic factor that is produced by tumor cells, Nagle *et al.*³⁰ discovered a new indanone in extracts of the marine cyanobacterium *Lyngbya majuscula*. Although the indanone inhibited VEGF expression (IC₅₀ = 25 μM) in transfected human hepatocellular carcinoma Hep3B cells, it appears unlikely that further *in vivo*




FIGURE 2 – CONTINUED

evaluation will be pursued because it did not inhibit Hep3B cell growth.

Luesch *et al.*³¹ reported on the isolation, structure determination and biological activity of a novel depsipeptide Lyngbyabellin A from the marine cyanobacterium *Lyngbya majuscula*. Although Lyngbyabellin A was observed to be cytotoxic to human nasopharyngeal and colon carcinoma cell lines (IC₅₀ ranging from 0.03 to 0.5 μg/mL, respectively) and to disrupt specifically cellular microfilament networks in smooth muscle cells at concentrations of 0.01–5 μg/mL, it lacked *in vivo* activity when tested at sublethal doses against murine colon or mammary adenocarcinomas.

As part of their project to investigate novel drugs to treat chemotherapy-insensitive tumors, Nakazawa *et al.*³² extended the pharmacology of Jaspamide, a depsipeptide isolated from sponges of the genus *Jaspis* and *Hemiasrella* using the HL-60 human promyelocytic leukemia cell line. Experimentation with cytogenetic and flow cytometric analysis of DNA revealed that nanomolar concentrations of Jaspamide induced inhibition of cell proliferation and an increase in polynuclear cells. Although the mechanism of polyploidy induction by Jaspamide remains undetermined at this time, this is a significant investigation because it contributes to the current knowledge of mechanisms involved in the molecular control of polyploidy, deemed essential for the understanding of cancer progression.

Aoki *et al.*³³ isolated 2 novel tetramic acids, Melophlins A and B from the sponge *Melophlus sarassinorum*, which reversed the ras-transformed phenotype of NIH3T3 fibroblasts at 5 μg/mL. Cell cycle analysis by flow cytometry demonstrated that Melophlins A and B arrested ras-transformed fibroblasts in the G₁ phase of the cell cycle, thus suggesting that because Melophlins reverse the

transformed phenotype, these moderately cytotoxic marine agents may have potential as a new type of anticancer agent.

Cuadros *et al.*³⁴ reported on the effects of Spisulosine, an alkyl amino alcohol isolated from the clam *Spisula polynyma*, on the growth and morphology of several cell lines. A striking observation was that Spisulosine promoted disassembly of actin stress fibers, whose formation is regulated by the small GTP-binding protein Rho. Thus, although the authors acknowledged that the specific molecular target of Spisulosine was as yet undetermined, they speculated that perhaps this marine chemical could act as an antagonist of the lysophosphatidic acid receptor or perhaps also play a role as an antagonist for sphingosine-1 receptor. Furthermore because Spisulosine “abolishes Rho activity [it] could have an obvious role as antitumoral agent.”³⁴

2000 ANTITUMOR PHARMACOLOGY OF MARINE NATURAL PRODUCTS WITH UNDETERMINED MECHANISMS OF ACTION

Table II encompasses 124 marine natural products that demonstrated activity in cytotoxicity assays and selected structures are shown in Figure 2. In contrast with the extensive preclinical and clinical investigation completed with the marine compounds presented in Table I, no detailed mechanism of action research was performed with most of the marine compounds shown in Table II, with the notable exception of 2 interesting articles. Zhou *et al.*³⁵ studied 2 novel Manzamine alkaloids in a novel antiangiogenesis assay, while Hirano *et al.*³⁶ showed that Ma'edamine A had inhibitory activity against the *c-erbB-2* kinase *in vitro*. In all the other studies listed in Table II, the marine compounds were tested in cytotoxicity assays that most

TABLE I – 2000 ANTITUMOR PHARMACOLOGY OF MARINE NATURAL PRODUCTS WITH DETERMINED MECHANISMS OF ACTION

Compound	Organism	Chemistry	Experimental or clinical model	Mechanism of action	Country	Reference
Aragusterol A	Sponge	Steroid	Human and murine cancer cell panel and <i>in vivo</i> assays	Targets the G ₁ /S cell cycle phase	Japan	26
Ascididemin	Tunicate	Alkaloid	Human and murine leukemia cell lines	Induction of apoptosis; no effect on topoisomerase I and II	France	27
Ascididemin	Tunicate	Alkaloid	Murine leukemia cell line	Reductive DNA cleavage by reactive oxygen species	United States, New Zealand	28
Bryostatin-1	Bryozoa	Macrolide	Human lymphoma cell line	Sensitizes cells to radiation-mediated antiproliferation	United States	6
Bryostatin-1	Bryozoa	Macrolide	Murine <i>in vivo</i> tumor model	Paclitaxel-Bryostatin combination is sequence-dependent	United States	7
Bryostatin-1	Bryozoa	Macrolide	Murine <i>in vivo</i> xenograft model for diffuse large cell lymphoma	Bryostatin enhances CHOP regimen for diffuse large cell lymphoma	United States	8
Cryptophycins	Bacteria	Depsipeptide	Bovine brain tubulin	Tight noncovalent binding to a tubulin high-affinity site	United States	11
Cryptophycins	Bacteria	Depsipeptide	Murine <i>in vivo</i> xenograft models	Effective in combination with doxorubicin, paclitaxel and 5-fluorouracil	United States	12
Cryptophycins	Bacteria	Depsipeptide	Murine <i>in vivo</i> xenograft models	Effective in a number of clinical combination regimens	United States	13
Didemnin B	Tunicate	Depsipeptide	Rabbit reticulocyte lysate and human adenocarcinoma cell line	Intact depsipeptide ring required for protein synthesis inhibition	United States	14
Discodermolide	Sponge	Polyketide	Human and murine tumor cell lines	Apoptosis as a potential mechanism of synergy with paclitaxel	United States	17
Ecteinascidin-743	Tunicate	Isoquinoline alkaloid	Human colon carcinoma cell line	Inhibition of human P glycoprotein gene (MDR1) transcription	United States	19
Ecteinascidin-743	Tunicate	Isoquinoline	Transfected NIH 3T3 fibroblasts	Promoter-specific transcription interference	Italy, United States	20
Ecteinascidin-743	Tunicate	Isoquinoline	Molecular dynamics	Minor groove widening and bending toward major groove and putative protein-DNA interactions	Spain	21,22
Eleutherobin analogues	Coral	Diterpene glycoside	Human breast carcinoma cell line	Eleutherobin pharmacophore B region necessary for tubulin binding	Canada, Brazil, The Netherlands	24
Eleutherobin analogues	Coral	Diterpene	Human breast carcinoma cell line	Enhanced antimitotic activity	Canada	25
Fascaplysin	Sponge	Alkaloid	Human colon carcinoma and osteogenic sarcoma cell lines and normal fibroblasts	Cyclin-dependent kinase 4 inhibition	Switzerland	29
Indanone from <i>Lyngbya majuscula</i>	Bacteria	Polyketide	Human hepatocellular carcinoma cell line	VEGF expression inhibition	United States	30
Jaspamide	Sponge	Depsipeptide	Human promyelocytic leukemia cell line	Induction of polyploidization	Japan	32
Lyngbyabellin A	Bacteria	Depsipeptide	Human nasopharyngeal and colon carcinoma cell line	Disruption of cellular microfilaments	United States	31
Melophlins A and B	Sponge	Tetramic acids	Human c-H-ras-transformed NIH3T3 cell line	Reversal of transformed phenotype to normal	Japan, Indonesia	33
Spisulosine	Clam	Alkyl amino alcohol	Monkey fibroblast cell lines	Disassembly of actin stress fibers	Spain, United States	34

commonly consisted of panels of either human or murine tumor cell lines. In a few reports, cytotoxicity studies were very extensive and included the National Cancer Institute 60-tumor cell line screen.^{37–42} A number of these novel compounds

showed significant cytotoxic activity, defined as an IC₅₀ of ≤ 4.0 μg/mL, and would appear as possible candidates for additional mechanism-of-action studies. This would help determine if the reported cytotoxicity was the result of a pharmacologic

TABLE II - 2000 ANTITUMOR PHARMACOLOGY OF MARINE NATURAL PRODUCTS WITH UNDETERMINED MECHANISM OF ACTION

Compound	Organism	Chemistry	Experimental or clinical tumor model	Growth inhibition or cytotoxicity	Country	Reference
Alkanes and Alkenes	Tunicate	Alkyl sulfate	Murine tumor cell lines	12-500 µg/mL	Italy	44
Aminols A and B	Tunicate	Alkyl amine	Murine tumor cell lines	2.1 µg/mL	Japan	45
Amphidinolide T	Dinoflagellate	Macrolide	Murine tumor cell line	18 µg/mL	Japan	46
Amphidinolide V	Dinoflagellate	Macrolide	Human and murine tumor cell line	3.2-7 µg/mL	Japan	47
Auroralis	Sponge	Sesquiterpene	Human tumor cell lines	0.2-8 µg/mL	France	48
Brassicole	Coral	Diterpene	Human and murine tumor cell lines	0.9-3.6 µg/mL	Taiwan	49
Calcegeoside B, C ₁ and C ₂	Sea cucumber	Triterpene glycoside	Human and murine tumor cell lines	5 µg/mL	Russia, Spain	50
Chondropsins A and B	Sponge	Macrolide	NCI 60 tumor cell line screen	2.4 × 10 ⁻⁸ M	United States	37
Colopsin E	Dinoflagellate	Alkyl glycoside	Murine tumor cell line	7 µg/mL	Japan	51
Crassolide, sarco- and 13-acetoxy-sarco-	Coral	Diterpene	Human and murine tumor cell lines	0.16-22.4 µg/mL	Taiwan	52
Crassolide, lobo-	Coral	Diterpene	Human and murine tumor cell lines	0.012-2.99 µg/mL	Taiwan	53
Cribrostansin 3-5	Sponge	Isoquinoline alkaloid	NCI 60 tumor cell line screen	1-10 × 10 ⁻⁶ M	United States	38
Hachijodins A-G	Sponge	Alkyl pyridine	Murine tumor cell lines	1-2.2 µg/mL	Japan, The Netherlands	54
Haligrammides A and B	Sponge	Peptide	Human tumor cell lines	A, 5.17-9.08 µg/mL; B, 3.89-8.82 µg/mL	United States	39
Hamiגרans	Sponge	Terpene	Murine tumor cell lines	8-74.2 µM	New Zealand	55
Hemilactones A and B	Bacterium	Alkaloid	Murine tumor cell lines	2.2-5.5 µM	United States	56
Homilactones	Sponge	Sesquiterpene	Murine and human cell lines	1 µg/mL	United States, New Zealand	57
IB-96212	Bacterium	Macrolide	Human and murine tumor cell lines	0.0001-1 µg/mL	Spain	58
Ineleganone	Coral	Diterpene	Human and murine tumor cell lines	0.2-3.63 µg/mL	Taiwan	59
Jorunycin	Nudibranch	Isoquinoline alkaloid	Human and murine tumor cell lines	0.0125 µg/mL	Italy, India	60
Ma'edamines A and B	Sponge	Alkaloid	Human and murine tumor cell lines and c-erbB-2-kinase	3.9-6.7 µg/mL	Japan, Australia	36
Malyngamide O	Sea hare	Alkaloid	Human and murine tumor cell lines	2 µg/mL	United States	61
Mangicols	Fungus	Sesquiterpene	NCI 60 tumor cell line screen	17-36.3 µM	United States	40
Epi-Manzamine D	Sponge	Alkaloid	Human and murine tumor cell lines and yeast antiangiogenesis assay	0.1-5 µg/mL	United States	35
Matemone	Sponge	Alkaloid	Human tumor cell lines	24-30 µg/mL	France	62
Microcyclicamide	Bacterium	Peptide	Murine tumor cell lines	1.2 µg/mL	Japan	63
Microsclerodermins	Sponge	Peptide	Human tumor cell line	1.1-2.4 µg/mL	United States	64
Mycalamides C and D	Sponge	Alkaloid	Murine tumor cell line	0.035-0.095 µg/mL	New Zealand, Australia	65
Mycalamide D	Sponge	Alkaloid	Human and murine tumor cell lines	0.006-0.019 µM	New Zealand	66
Neomarnone	Bacterium	Quinone	NCI 60 tumor cell line screen	8-10 µg/mL	United States	42
Pachyclavularioline F	Coral	Diterpene	Murine tumor cell line	1 µg/mL	Canada, The Netherlands	67
Pellynol L	Sponge	Polyacetylene	Human tumor cell lines	0.08-2.23 µg/mL	United States	68
Peloruside A	Sponge	Macrolide	Murine tumor cell lines	0.010 µg/mL	New Zealand	69
Plakortides I and J	Sponge	Polyketide	Murine tumor cell lines	7-9 µg/mL	Italy	70
Pyrimodems B-D	Sponge	Alkyl pyridine	Human and murine tumor cell lines	0.06-0.5 µg/mL	Japan	71
Risseins A and B	Sponge	Alkaloid	Human tumor cell line	2.0 µg/mL	Brazil, United States	72
Sansalvamide, N-methyl	Coral	Steroidal glycoside	Human tumor cell line	Mean, 8.3 µM	United States	41
Secosterol, epoxy	Fungus	Depsipeptide	NCI 60 tumor cell line screen	11-18.43 µg/mL	United States	73
Stauroporines	Gorgonian	Steroid	Human tumor cell lines	0.002-0.04 µM	Spain	74
Stelliferins, hydroxy	Bacterium	Alkaloid	Human and murine tumor cell lines	0.06-1.3 µM	Japan	75
Oxysterol	Sponge	Triterpene	Murine tumor cell lines	0.9-9.7 µg/mL	Korea	76
Peroxysterols	Gorgonian	Steroid	Human tumor cell line	0.4-10.8 µg/mL	Taiwan	77
Peroxysterol	Coral	Steroid	Human and murine tumor cell lines	< 80 µg/mL	France	78
Steroidal Dione	Sponge	Steroid	Human and murine tumor cell lines	1 µg/mL	Spain	79
Steroidal Dione	Alga	Steroid	Human tumor cell line	0.5 µg/mL	France	80
Sterol, hydroxytheonella	Sponge	Steroid	Human tumor cell line	29.5 µM	United States	81
Stolicic acids A and B	Ascidian	Fatty acid	Human tumor cell lines	0.05-0.1 µg/mL	United States	82
Stolonoxides A-D	Ascidian	Fatty acid	Human and murine tumor cell lines	0.01-1 µg/mL	Spain	83
Strongyloidols A-C	Sponge	Polyacetylene	Human tumor cell lines	0.35-28 µg/mL	Japan, The Netherlands	84
Suberosanols	Gorgonian	Sesquiterpene	Murine and human tumor cell lines	5 × 10 ⁻⁶ to 50 µg/mL	Taiwan	77
Sulcatin	Tunicate	Alkaloid	Murine tumor cell line	3-65 µg/mL	Italy	85
Tamandarin A and B	Tunicate	Depsipeptide	Human tumor cell line	0.99-1.79 ng/mL	United States, Brazil	86
Triene aldehyde	Sponge	Fatty Acid	Human tumor cell line	10 µg/mL	Japan	87

¹For significant activity of pure compounds, an IC₅₀ of ≤ 4.0 µg/mL is required.

rather than a toxic effect on the tumor cell used for the reported investigation.

CONCLUSION

This review highlights the fact that antitumor marine pharmacology research in 2000 remained on a combination pharmacological approach between research focused on determining the mechanism of action of cytotoxic agents, and studies with novel agents discovered to be active against specific cancer-related targets. Although our review has mainly focused on the pharmacology rather than the pharmaceutical development of marine anticancer agents, it should be noted that concomitant to the mechanistic characterization of novel marine cytotoxic or antitumor agents, the issues of supply, formulation and manufacturing are extremely important for the successful development of novel pharmaceutical agents. A review published during 2000 documents the importance of these different issues in the current development of Didemnin B, Bryostatins, Dolastatins and Ecteinascidins.⁴³

Even if during 2000 no new marine natural product was approved for patient treatment by the U.S. Food and Drug Administration, the present 2000 antitumor and cytotoxic overview provides abundant evidence that 50 years after the discovery by Bergman *et al.* of Spongothymidine and Spongouridine, there continued to be a sustained and persistent multinational effort aimed at the discovery of novel and clinically useful antitumor agents derived from marine organisms.

ACKNOWLEDGEMENTS

This publication was made possible by grant number R03 ES10138-01 (to A.M.S.M) from the National Institute of Environmental Health Sciences, National Institutes of Health. The excellent support for literature searches and article retrieval by library staff members as well as medical and pharmacy students of Midwestern University is most gratefully acknowledged. The authors thank Mrs. Victoria Sears for excellent secretarial assistance in the preparation of this article.

REFERENCES

- Mayer AMS, Lehmann VKB. Marine pharmacology in 1999: antitumor and cytotoxic compounds. *Anticancer Res* 2001;21:2489–500.
- Mayer AMS. Marine Pharmacology in 1998: antitumor and cytotoxic compounds. *Pharmacologist* 1999;41:159–64.
- Supko JG, Lynch TJ, Clark JW, et al. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. *Cancer Chemother Pharmacol* 2000;46:319–28.
- Sogawa K, Yamada T, Sumida T, et al. Induction of apoptosis and inhibition of DNA topoisomerase-I in K-562 cells by a marine microalgal polysaccharide. *Life Sci* 2000;66:L227–31.
- Sangrajrang S, Zidane M, Berda P, et al. Different microtubule network alterations induced by pachymatinsin, a new marine glycoprotein, on two prostatic cell lines. *Cancer Chemother Pharmacol* 2000;45:120–6.
- Cartee L, Davis C, Lin PS, et al. Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism. *Int J Radiat Biol* 2000;76:1323–33.
- Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. *Clin Cancer Res* 2000;6:1498–507.
- Mohammad RM, Wall NR, Dutcher JA, et al. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. *Clin Cancer Res* 2000;6:4950–6.
- Pagliaro L, Daliani D, Amato R, et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. *Cancer* 2000;89:615–8.
- Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. *Clin Cancer Res* 2000;6:825–8.
- Panda D, Ananthnarayan V, Larson G, et al. Interaction of the antitumor compound cryptophycin-52 with tubulin. *Biochemistry* 2000;39:14121–7.
- Menon K, Alvarez E, Forler P, et al. Antitumor activity of cryptophycins: effect of infusion time and combination studies. *Cancer Chemother Pharmacol* 2000;46:142–9.
- Teicher BA, Forler P, Menon K, et al. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts. *In Vivo* 2000;14:471–80.
- Ahuja D, Geiger A, Ramanjulu JM, et al. Inhibition of protein synthesis by didemnins: cell potency and SAR. *J Med Chem* 2000;43:4212–8.
- Kucuk O, Young ML, Habermann TM, et al. Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. *Am J Clin Oncol* 2000;23:273–7.
- Nuijen B, Bouma M, Henrar RE, et al. Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. *PDA J Pharm Sci Technol* 2000;54:193–208.
- Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. *Clin Cancer Res* 2000;6:1978–87.
- Madden T, Tran HT, Beck D, et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. *Clin Cancer Res* 2000;6:1293–301.
- Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. *Proc Natl Acad Sci USA* 2000;97:6775–9.
- Minuzzo M, Marchini S, Brogini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. *Proc Natl Acad Sci USA* 2000;97:6780–4.
- Garcia-Nieto R, Manzanares I, Cuevas C, et al. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions? *J Med Chem* 2000;43:4367–9.
- Garcia-Nieto R, Manzanares I, Cuevas C, et al. Bending of DNA upon binding of ecteinascidin 743 and phthalascidin 650 studied by unrestrained molecular dynamics simulations. *J Am Chem Soc* 2000;122:7172–82.
- Van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. *Clin Cancer Res* 2000;6:4725–32.
- Cinel B, Roberge M, Behrisch H, et al. Antimitotic diterpenes from *Erythropodium caribaeorum* test pharmacophore models for microtubule stabilization. *Org Lett* 2000;2:257–60.
- Roberge M, Cinel B, Anderson HJ, et al. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. *Cancer Res* 2000;60:5052–8.
- Fukuoka K, Yamagishi T, Ichihara T, et al. Mechanism of action of aragusterol (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle. *Int J Cancer* 2000;88:810–9.
- Dassonneville L, Watez N, Baldeyrou B, et al. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. *Biochem Pharmacol* 2000;60:527–37.
- Matsumoto SS, Sidford MH, Holden JA, et al. Mechanism of action studies of cytotoxic marine alkaloids: ascididemin exhibits thiol-dependent oxidative DNA cleavage. *Tetrahedron Lett* 2000;41:1667–70.
- Soni R, Muller L, Furet P, et al. Inhibition of cyclin-dependent kinase 4 (Cdk4) by faspaplysin, a marine natural product. *Biochem Biophys Res Commun* 2000;275:877–84.
- Nagle DG, Zhou YD, Park PU, et al. A new indanone from the marine cyanobacterium *Lyngbya majuscula* that inhibits hypoxia-induced activation of the VEGF promoter in Hep3B cells. *J Nat Prod* 2000;63:1431–3.
- Luesch H, Yoshida WY, Moore RE, et al. Isolation, structure determination, and biological activity of lyngbyabellin A from the marine cyanobacterium *Lyngbya majuscula*. *J Nat Prod* 2000;63:611–5.
- Nakazawa H, Kitano K, Cioca DP, et al. Induction of polyploidization by jaspamide in HL-60 cells. *Acta Haematol* 2000;104:65–71.
- Aoki S, Higuchi K, Ye Y, et al. Melophlins A and B, novel tetramic acids reversing the phenotype of ras-transformed cells, from the marine sponge *Melophlus sarassinorum*. *Tetrahedron* 2000;56:1833–6.
- Cuadros R, de Garcini EM, Wandosell F, et al. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. *Cancer Lett* 2000;152:23–9.
- Zhou BN, Slebodnick C, Johnson RK, et al. New cytotoxic manzamine alkaloids from a palaun sponge. *Tetrahedron* 2000;56:5781–4.

36. Hirano K, Kubota T, Tsuda M, et al. Ma'edamines A and B, cytotoxic bromotyrosine alkaloids with a unique 2(1H)pyrazinone ring from sponge *Suberea* sp. *Tetrahedron* 2000;56:8107–10.
37. Cantrell CL, Gustafson KR, Cecere MR, et al. Chondropsins A and B: novel tumor cell growth-inhibitory macrolide lactams from the marine sponge *Chondropsis* sp. *J Am Chem Soc* 2000;122:8825–9.
38. Pettit GR, Knight JC, Collins JC, et al. Antineoplastic agents 430: isolation and structure of cribrostatins 3, 4, and 5 from the Republic of Maldives *Cribrochalina* species. *J Nat Prod* 2000;63:793–8.
39. Rashid MA, Gustafson KR, Boswell JL, et al. Haligramides A and B, two new cytotoxic hexapeptides from the marine sponge *Haliclona nigra*. *J Nat Prod* 2000;63:956–9.
40. Renner MK, Jensen PR, Fenical W. Mangicols: structures and biosynthesis of A new class of sesterterpene polyols from a marine fungus of the genus *Fusarium*. *J Org Chem* 2000;65:4843–52.
41. Cueto M, Jensen PR, Fenical W. N-methylsalsalvamide, a cytotoxic cyclic depsipeptide from a marine fungus of the genus *Fusarium*. *Phytochemistry* 2000;55:223–6.
42. Hardt IH, Jensen PR, Fenical W. Neomarinone, and new cytotoxic marinone derivatives, produced by a marine filamentous bacterium (actinomycetales). *Tetrahedron Lett* 2000;41:2073–6.
43. Nuijen B, Bouma M, Manada C, et al. Pharmaceutical development of anticancer agents derived from marine sources. *Anti-Cancer Drugs* 2000;11:793–811.
44. Aiello A, Carbonelli S, Esposito G, et al. Novel bioactive sulfated alkene and alkanes from the mediterranean ascidian *Halocynthia papillosa*. *J Nat Prod* 2000;63:1590–2.
45. Sata NU, Fusetani N, Amaminols A and B, new bicyclic amino alcohols from an unidentified tunicate of the family *Polyclimidae*. *Tetrahedron Lett* 2000;41:489–92.
46. Tsuda M, Endo T, Kobayashi J. Amphidinolide T, novel 19-membered macrolide from marine dinoflagellate *Amphidinium* sp. *J Org Chem* 2000;65:1349–52.
47. Kubota T, Tsuda M, Kobayashi J. Amphidinolide V, novel 14-membered macrolide from marine dinoflagellate *Amphidinium* sp. *Tetrahedron Lett* 2000;41:713–6.
48. Bourguet-Kondracki ML, Longeon A, Debitus C, et al. New cytotoxic isomalabaricane-type sesterterpenes from the New Caledonian marine sponge *Rhabdastrella globostellata*. *Tetrahedron Lett* 2000;41:3087–90.
49. Duh CY, Wang SK, Weng YL. Brassicolene, a novel cytotoxic diterpenoid from the Formosan soft coral *Nephtea brassica*. *Tetrahedron Lett* 2000;41:1401–3.
50. Avilov SA, Antonov AS, Drozdova OA, et al. Triterpene glycosides from the Far-Eastern sea cucumber *Pentamera calcigera*: I, mono-sulfated glycosides and cytotoxicity of their unsulfated derivatives. *J Nat Prod* 2000;63:65–71.
51. Kubota T, Tsuda M, Takahashi M, et al. Colopsinols D and E, new polyhydroxyl linear carbon chain compounds from marine dinoflagellate *Amphidinium* sp. *Chem Pharm Bull (Tokyo)* 2000;48:1447–51.
52. Duh CY, Wang SK, Chung SG, et al. Cytotoxic cembrenolides and steroids from the formosan soft coral *Sarcophyton crassocaule*. *J Nat Prod* 2000;63:1634–7.
53. Duh CY, Wang SK, Huang BT, et al. Cytotoxic cembrenolide diterpenes from the formosan soft coral *Lobophytum crassum*. *J Nat Prod* 2000;63:884–5.
54. Tsukamoto S, Takahashi M, Matsunaga S, et al. Hachijodines A-G: seven new cytotoxic 3-alkylpyridine alkaloids from two marine sponges of the genera *Xestospongia* and *Amphimedon*. *J Nat Prod* 2000;63:682–4.
55. Wellington KD, Cambie RC, Rutledge PS, et al. Chemistry of sponges: 19, novel bioactive metabolites from *Hamigera tarangaensis*. *J Nat Prod* 2000;63:79–85.
56. Tan LT, Okino T, Gerwick WH. Hermitamides A and B, toxic malonylamide-type natural products from the marine cyanobacterium *Lyngbya majuscula*. *J Nat Prod* 2000;63:952–5.
57. Jimenez JJ, Yoshida WY, Scheuer PJ, et al. Honulactones: new bishomosalcarane sesterterpenes from the Indonesian sponge *Strepsichordaia aliena*. *J Org Chem* 2000;65:6837–40.
58. Fernandez-Chimeno RI, Canedo L, Espliego F, et al. IB-96212, a novel cytotoxic macrolide produced by a marine *Micromonospora*: I, taxonomy, fermentation, isolation and biological activities. *J Antibiot (Tokyo)* 2000;53:474–8.
59. Chai MC, Wang SK, Dai CF, et al. A cytotoxic lobane diterpene from the formosan soft coral *Sinularia ineleigans*. *J Nat Prod* 2000;63:843–4.
60. Fontana A, Cavaliere P, Wahidulla S, et al. A new antitumor isoquinoline alkaloid from the marine nudibranch *Jorunna funebris*. *Tetrahedron* 2000;56:7305–8.
61. Gallimore WA, Scheuer PJ. Malyngamides O and P from the sea hare *Stylocheilus longicauda*. *J Nat Prod* 2000;63:1422–4.
62. Carletti I, Banaigs B, Amade P. Matemone, a new bioactive bromine-containing oxindole alkaloid from the Indian Ocean sponge *Iotrochota purpurea*. *J Nat Prod* 2000;63:981–3.
63. Ishida K, Nakagawa H, Murakami M. Microcyclamide, a cytotoxic cyclic hexapeptide from the cyanobacterium *Microcystis aeruginosa*. *J Nat Prod* 2000;63:1315–7.
64. Qureshi A, Colin PL, Faulkner DJ. Microsclerodermins F-I, antitumor and antifungal cyclic peptides from the lithistid sponge *Microscleroderma* sp. *Tetrahedron* 2000;56:3679–85.
65. Simpson JS, Garson MJ, Blunt JW, et al. Mycalamides C and D, cytotoxic compounds from the marine sponge *Stylinos* species. *J Nat Prod* 2000;63:704–6.
66. West LM, Northcote PT, Hood KA, et al. Mycalamide D, a new cytotoxic amide from the New Zealand marine sponge *Mycale* species. *J Nat Prod* 2000;63:707–9.
67. Xu L, Patrick BO, Roberge M, et al. New diterpenoids from the octocoral *Pachyclavularia violacea* collected in Papua New Guinea. *Tetrahedron* 2000;56:9031–7.
68. Rashid MA, Gustafson KR, Boyd MR. Pellynol I, a new cytotoxic polyacetylene from the sponge *Pellina* sp. *J Nat Prod* 2000;14:387–92.
69. West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge *Mycale* sp. *J Org Chem* 2000;65:445–9.
70. Fattorusso E, Tagliatalata-Scafati O, Di Rosa M, et al. Metabolites from the sponge *Plakortis simplex*: 3, isolation and stereostructure of novel bioactive cycloperoxides and diol analogues. *Tetrahedron* 2000;56:7959–67.
71. Hirano K, Kubota T, Tsuda M, et al. Pyrinodems B-D, potent cytotoxic bis-pyridine alkaloids from marine sponge *Amphimedon* sp. *Chem Pharm Bull (Tokyo)* 2000;48:974–7.
72. Maia LF, Epifanio RA, Fenical W. New cytotoxic sterol glycosides from the octocoral *Carijoa (Telesto) riisei*. *J Nat Prod* 2000;63:1427–30.
73. Naz S, Kerr RG, Narayanan R. New antiproliferative epoxysecosterols from *Pseudopterogorgia americana*. *Tetrahedron Lett* 2000;41:6035–40.
74. Hernandez LM, Blanco JA, Baz JP, et al. 4'-N-methyl-5'-hydroxystaurosporine and 5'-hydroxystaurosporine, new indolocarbazole alkaloids from a marine *Micromonospora* sp. strain. *J Antibiot (Tokyo)* 2000;53:895–902.
75. Oku N, Matsunaga S, Wada S, et al. New isomalabaricane triterpenes from the marine sponge *Stelletta globostellata* that induce morphological changes in rat fibroblasts. *J Nat Prod* 2000;63:205–9.
76. Rho J. New bioactive steroids from the Gorgonian *Acalyngorgia Inermis*. *Bull Korean Chem Soc* 2000;21:518–20.
77. Sheu JH, Chang KC, Duh CY. A cytotoxic 5 α ,8 α -epidioxy-sterol from a soft coral *Sinularia* species. *J Nat Prod* 2000;63:149–51.
78. Gauvin A, Smadja J, Akinin M, et al. Isolation of bioactive 5 α ,8 α -epidioxy sterols from the marine sponge *Luffariella cf. variabilis*. *Can J Chem* 2000;78:986–92.
79. Garrido L, Zubia E, Ortega MJ, et al. Isolation and structure elucidation of new cytotoxic steroids from the gorgonian *Leptogorgia sarmentosa*. *Steroids* 2000;65:85–8.
80. Ktari L, Blond A, Guyot M. 16 β -hydroxy-5 α -cholestane-3,6-dione, a novel cytotoxic oxysterol from the red alga *Jania rubens*. *Bioorg Med Chem Lett* 2000;10:2563–5.
81. Qureshi A, Faulkner DJ. 7 α -hydroxytheonellasterol, a cytotoxic 4-methylene sterol from the Philippines sponge *Theonella swinhoei*. *J Nat Prod* 2000;63:841–2.
82. Davies-Coleman MT, Gustafson KR, Cantrell CL, et al. Stoloniac acids A and B, new cytotoxic cyclic peroxides from an Indian Ocean ascidian *Stolonica* species. *J Nat Prod* 2000;63:1411–3.
83. Duran R, Zubia E, Ortega MJ, et al. Minor metabolites from the ascidian *Stolonica socialis* and cytotoxicity of stolonoxides. *Tetrahedron* 2000;56:6031–7.
84. Watanabe K, Tsuda Y, Yamane Y, et al. Strongylodiols A, B and C, new cytotoxic acetylenic alcohols isolated from the Okinawan marine sponge of the genus *Strongylophora* as each enantiomeric mixture with a different ratio. *Tetrahedron Lett* 2000;41:9271–6.
85. Aiello A, Fattorusso E, Menna M, et al. Sulcatin, a novel antiproliferative N-methylpyridinium alkaloid from the ascidian *Microcosmus vulgaris*. *J Nat Prod* 2000;63:517–9.
86. Vervoort H, Fenical W, Epifanio RA. Tamandarins A and B: new cytotoxic depsipeptides from a Brazilian ascidian of the family didemniidae. *J Org Chem* 2000;65:782–92.
87. Watanabe K, Tsuda Y, Iwashima M, et al. A new bioactive triene aldehyde from the marine sponge *Leucetta microraphis*. *J Nat Prod* 2000;63:258–60.